Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (FLCN)

Oncogene

Volumn 33, Issue 8, 2014, Pages 956-965

  Lu, X ^a   Boora, U ^a   Seabra, L ^a   Rabai, E M ^a   Fenton, J ^a   Reiman, A ^a   Nagy, Z ^a   Maher, E R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Birt Hogg Dub ; Caspase; Folicullin; Slingshot phosphatases; Synthetic lethality; Therapeutic target

Indexed keywords

CARCINOMA, RENAL CELL; CASPASE 3; CELL LINE, TUMOR; ENZYME ACTIVATION; GENE KNOCKDOWN TECHNIQUES; GENES, TUMOR SUPPRESSOR; HUMANS; KIDNEY NEOPLASMS; PHOSPHOPROTEIN PHOSPHATASES; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84894574272     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.27     Document Type: Article

References (30)

1. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 1317-1320
2. Foster K, Prowse A, Van Den Berg A, Fleming S, Hulsbeek MM, Crossey PA et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genetic 1994; 3: 2169-2173
3. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7: 85-90
4. Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, Cohen D et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006; 66: 2000-2011
5. Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 2006; 12: 7215-7220
6. Motzer RJ, Hudes G, Wilding G, Schwartz LH, Hariharan S, Kempin S et al. Phase I trial of sunitinib malate plus interferon-Alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2009; 7: 28-33
7. Toro JR, Wei MH, Glenn GM, Weinreich M, Toure O, Vocke C et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: A new series of 50 families and a review of published reports. J Med Genetic 2008; 45: 321-331
8. Menko FH, van Steensel MA, Giraud S, Friis-Hansen L, Richard S, Ungari S et al. Birt-Hogg-Dube syndrome: Diagnosis and management. Lancet Oncol 2009; 10: 1199-1206
9. Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner ML et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2002; 2: 157-164
10. Schmidt LS, Nickerson ML, Warren MB, Glenn GM, Toro JR, Merino MJ et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome. Am J Hum Genetic 2005; 76: 1023-1033
11. Lim DH, Rehal PK, Nahorski MS, Macdonald F, Claessens T, Van Geel M et al. A new locus-specific database (LSDB) for mutations in the folliculin (FLCN) gene. Hum Mutat 2009; 31: E1043-E1051
12. da Silva NF, Gentle D, Hesson LB, Morton DG, Latif F, Maher ER. Analysis of the Birt-Hogg-Dube (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer. J Med Genetic 2003; 40: 820-824
13. Baba M, Furihata M, Hong SB, Tessarollo L, Haines DC, Southon E et al. Kidneytargeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and AktmTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst 2008; 100: 140-154
14. Chen J, Futami K, Petillo D, Peng J, Wang P, Knol J et al. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia. PloS One 2008; 3: E3581
15. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle. (Georgetown, Tex 2011; 10: 1192-1199
16. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 2010; 376: 235-244
17. Rehman FL, Lord CJ, Ashworth A. Synthetic lethal approaches to breast cancer therapy. Nat RevClin Oncol 2010; 7: 718-724
18. Yang Y, Padilla-Nash HM, Vira MA, Abu-Asab MS, Val D, Worrell R et al. The UOK 257 cell line: A novel model for studies of the human Birt-Hogg-Dube gene pathway. Cancer Genetic Cytogenet 2008; 180: 100-109
19. Plastino J, Sykes C. The actin slingshot. Curr Opin Cell Biol 2005; 17: 62-66
20. Huang TY, DerMardirossian C, Bokoch GM. Cofilin phosphatases and regulation of actin dynamics. Curr Opin Cell Biol 2006; 18: 26-31
21. Mizuno K. Signaling mechanisms and functional roles of cofilin phosphorylation and dephosphorylation. Cellular Signal 2012; 25: 457-469
22. Lu X, Wei W, Fenton J, Nahorski MS, Rabai E, Reiman A et al. Therapeutic targeting the loss of the birt-hogg-dube suppressor gene. Mol Cancer Ther 2011; 10: 80-89
23. Bernstein BW, Bamburg JR. ADF/cofilin: A functional node in cell biology. Trends Cell Biol 2010; 20: 187-195
24. Posadas I, Perez-Martinez FC, Guerra J, Sanchez-Verdu P, Cena V. Cofilin activation mediates Bax translocation to mitochondria during excitotoxic neuronal death. J Neurochem 2012; 120: 515-527
25. Kaelin WG. The von Hippel-Lindau tumor suppressor protein: Roles in cancer and oxygen sensing. Cold Spring Harb Symp Quant Biol 2005; 70: 159-166
26. Kaelin Jr. WG. Treatment of kidney cancer: Insights provided by the VHL tumorsuppressor protein. Cancer 2009; 115(10 Suppl): 2262-2272
27. Reinhardt HC, Jiang H, Hemann MT, Yaffe MB. Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle. (Georgetown, Tex 2009; 8: 3112-3119
28. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134
29. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-deficient cells rely on ATM- And ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007; 11: 175-189
30. Lu X, Errington J, Curtin NJ, Lunec J, Newell DR. The impact of p53 status on cellular sensitivity to antifolate drugs. Clin Cancer Res 2001; 7: 2114-2123.